Webb13 apr. 2024 · Combination therapy with the novel agent BXCL701 and pembrolizumab showed strong clinical activity in in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant ... and 50% had prior taxane chemotherapy. The median duration of follow-up was 30.8 weeks (range, 1.9-86.9), and … WebbEpithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related death. The high mortality and morbidity associated with EOC are mostly due to late diagnosis and chemotherapy drug resistance. Currently, the standard first-line chemotherapy regimen is systemic administration of platinum-based chemotherapy combined with a taxane. A …
Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During ...
Webb9 feb. 2012 · platinum-resistant disease taxane-pretreated disease age: 20–75 years old PS (performance status): 0–2 one of the followings, or both of them: patients have measurable lesion patients have assessable lesion with elevated CA-125 (more than 70 U/ml) no prior treatment with irinotecan, topotecan or etoposide no prior radiation to … Webb21 sep. 2016 · The cellular toxicity of taxanes and platinum agents are likely controlled by the actions of multiple genes. 8 - 10 Genes involved in transport (eg, ABCB1, ABCC1, and ABCC2 ), metabolism (cytochrome P450s), and pharmacodynamics (eg, TP53, CDKN1A) all appear to play a role in taxane efficacy. 9 Similarly, platinum agents such as carboplatin … nursing home chico ca
Dr. Ashish Vora, PhD - Manager in the KnowledgeBase - Linkedin
Webb14 apr. 2024 · Purpose Sarcopenia is prevalent in ovarian cancer and contributes to poor survival. This study is aimed at investigating the association of prognostic nutritional index (PNI) with muscle loss and survival outcomes in patients with ovarian cancer. Methods This retrospective study analyzed 650 patients with ovarian cancer treated with primary … Webbmanaging platinum and taxane agent HSRs, continued im-provements can be made to refine existing risk stratification strategies for patients with platinum and taxane HSRs. TABLE I. Four-step reintroduction protocols reported for carboplatin1,7-9 Step Pradelli et al1 Takase et al7 Altwerger et al8 Li et al9 1 1:1000 1:1000 1:1000 1:1 Webb2 juli 2024 · This study evaluates the safety and efficacy of the combination of Avelumab, (a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody) in combination with a taxane chemotherapy (docetaxel) in patients with metastatic urothelial cancer who are either ineligible to receive cisplatin based chemotherapy, refractory to cisplatin in first … nj community health center